304 related articles for article (PubMed ID: 24730335)
1. [Researchers illuminate diabetes therapy].
Pflege Z; 2014 Feb; 67(2):126. PubMed ID: 24730335
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of insulin glargine added to a fixed-dose combination of metformin and a dipeptidyl peptidase-4 inhibitor: results of the GOLD observational study.
Seufert J; Pegelow K; Bramlage P
Vasc Health Risk Manag; 2013; 9():711-7. PubMed ID: 24259985
[TBL] [Abstract][Full Text] [Related]
3. Comparison of insulin glargine and liraglutide added to oral agents in patients with poorly controlled type 2 diabetes.
D'Alessio D; Häring HU; Charbonnel B; de Pablos-Velasco P; Candelas C; Dain MP; Vincent M; Pilorget V; Yki-Järvinen H;
Diabetes Obes Metab; 2015 Feb; 17(2):170-8. PubMed ID: 25359159
[TBL] [Abstract][Full Text] [Related]
4. Twice-daily pre-mixed insulin rather than basal insulin therapy alone results in better overall glycaemic control in patients with Type 2 diabetes.
Malone JK; Bai S; Campaigne BN; Reviriego J; Augendre-Ferrante B
Diabet Med; 2005 Apr; 22(4):374-81. PubMed ID: 15787659
[TBL] [Abstract][Full Text] [Related]
5. Improved glycemic control with insulin glargine versus pioglitazone as add-on therapy to sulfonylurea or metformin in patients with uncontrolled type 2 diabetes mellitus.
Meneghini LF; Traylor L; Schwartz SL
Endocr Pract; 2010; 16(4):588-99. PubMed ID: 20350924
[TBL] [Abstract][Full Text] [Related]
6. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
7. Summaries for patients. Exenatide or insulin glargine for suboptimally controlled diabetes?
Ann Intern Med; 2005 Oct; 143(8):I30. PubMed ID: 16230718
[No Abstract] [Full Text] [Related]
8. [Early insulin treatment in type 2 diabetes--yes].
Schumm-Draeger PM
Dtsch Med Wochenschr; 2013 May; 138(18):956. PubMed ID: 23613375
[No Abstract] [Full Text] [Related]
9. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial.
Barnett AH; Burger J; Johns D; Brodows R; Kendall DM; Roberts A; Trautmann ME
Clin Ther; 2007 Nov; 29(11):2333-48. PubMed ID: 18158075
[TBL] [Abstract][Full Text] [Related]
10. Summaries for patients: Does adding exenatide to insulin treatment benefit patients with type 2 diabetes?
Ann Intern Med; 2011 Jan; 154(2):I-40. PubMed ID: 21135289
[No Abstract] [Full Text] [Related]
11. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
12. [Therapy with incretin mimetic exenatide. Soon HbA1c value and weight decrease permanently].
MMW Fortschr Med; 2006 Sep; 148(37):55. PubMed ID: 17036908
[No Abstract] [Full Text] [Related]
13. [Sequential treatment with insulin glargine and metformin, and exenatide in a patient with newly diagnosed type-2 diabetes].
Kress S
Dtsch Med Wochenschr; 2010 May; 135(18):907-10. PubMed ID: 20425675
[TBL] [Abstract][Full Text] [Related]
14. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients.
Rosenstock J; Sugimoto D; Strange P; Stewart JA; Soltes-Rak E; Dailey G
Diabetes Care; 2006 Mar; 29(3):554-9. PubMed ID: 16505505
[TBL] [Abstract][Full Text] [Related]
15. Starting insulin therapy in type 2 diabetes: lesson 1.
McCall AL
Curr Diab Rep; 2005 Oct; 5(5):325-6. PubMed ID: 16188164
[No Abstract] [Full Text] [Related]
16. [When oral therapy of type 2 diabetes fails--basal insulin is more effective than change in life style (interview by Dr. Thomas Meissner)].
MMW Fortschr Med; 2008 Aug; 150(32-35):28-9. PubMed ID: 19006878
[No Abstract] [Full Text] [Related]
17. The longest ever randomised controlled trial of insulin glargine: study design and HbA(1c) findings.
Currie CJ
Diabetologia; 2009 Oct; 52(10):2234-5; author reply 2236-9. PubMed ID: 19662377
[No Abstract] [Full Text] [Related]
18. [Insulin glargine. The most studied basal insulin].
Walter M
MMW Fortschr Med; 2013 Nov; 155(19):70-1. PubMed ID: 24475676
[No Abstract] [Full Text] [Related]
19. [Improving insulin therapy in type 2 diabetes. Conquering barriers and assuring quality of life].
MMW Fortschr Med; 2014 Dec; 156(21-22):99. PubMed ID: 25608421
[No Abstract] [Full Text] [Related]
20. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study.
Blicklé JF; Hancu N; Piletic M; Profozic V; Shestakova M; Dain MP; Jacqueminet S; Grimaldi A
Diabetes Obes Metab; 2009 Apr; 11(4):379-86. PubMed ID: 19087105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
